Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.



Esperion Therapeutics (NASDAQ: ESPR) 3:28 PM ET on Apr 20, 2018
Last Price 73.56 Change -0.60(-0.809%) open 73.95 Day High 75.68 52-Week High 82.68
Volume 160,744 Previous Close 74.16 Day Low 72.88 52-Week Low 30.95

Press Releases

Load More